Security key
230770109
CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX)
CUSIP: 230770109
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common stock
- Total 13F shares
- 25,413
- Total 13F value
- $164,849
- Share change
- +24,976
- SEC-reported price per share
- $6.49
- Number of holders
- 3
- Value change
- +$161,849
- Number of buys
- 2
- Shares outstanding
- 15,075,924
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
CPIX full security history
Ownership snapshot
Full 13F holder table
CUMBERLAND PHARMACEUTICALS INC SEC filings
CUMBERLAND PHARMACEUTICALS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 230770109
Recent filing periods:
Ownership snapshot
Top reported holders of CPIX - CUMBERLAND PHARMACEUTICALS INC - Common stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
A. J. Kazimi
Disclosed value leader
A. J. Kazimi
Comparable rows
15/15
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 38%
13D/G row: A. J. Kazimi
Showing 1-6 of 15 holder rows.
Quick read
A. J. Kazimi leads the comparable SEC ownership view at 38%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens A. J. Kazimi's linked filing trail.
Comparable ownership
Top 5
A. J. Kazimi
38%
Ikarian Capital, LLC
4.9%
INTEGRATED CORE STRATEGIES (US) LLC
4%
Kenneth Krogulski
2%
Joseph C. Galante
0.42%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| A. J. Kazimi |
3/4/5
13D/G
Chairman and CEO, Director, 10%+ Owner
|
38%
from 13D/G
|
$27,934,548
6,263,310 shares
mixed-class rows
|
+$817 | 18 Mar 2026 |
| Ikarian Capital, LLC |
13D/G
13F
Company
|
4.9%
|
$3,545,020
730,932 shares
|
$0 | 31 Mar 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
4%
|
$1,618,467
598,634 shares
|
-$571,171 | 30 Sep 2025 |
| Kenneth Krogulski |
3/4/5
Director
|
2%
|
$1,354,474
302,338 shares
|
+$4,282 | 18 Mar 2026 |
| Joseph C. Galante |
3/4/5
Director
|
0.42%
|
$285,178
63,656 shares
|
— | 18 Mar 2026 |
| James Jones |
3/4/5
Director
|
0.31%
|
$209,946
46,863 shares
|
+$817 | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
25,413
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
28
Q2 2026 holders
3
Holder diff
-25
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend